P970: A REAL-WORLD RETROSPECTIVE-PROSPECTIVE ANALYSIS OF EFFICACY AND SAFETY OF COMBINED IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE NORTHERN ITALY EXPERIENCE

Ижил төстэй зүйлс

• Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM)
  -н: Josip Batinić, зэрэг
  Хэвлэсэн: (2024-11-01)
• Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma – case series and literature review
  -н: Aneta Szudy-Szczyrek, зэрэг
  Хэвлэсэн: (2021-06-01)
• Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma
  -н: Yan Wang, зэрэг
  Хэвлэсэн: (2025-02-01)
• Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma
  -н: Maral DerSarkissian, зэрэг
  Хэвлэсэн: (2023-12-01)
• Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice
  -н: Jiri Minarik, зэрэг
  Хэвлэсэн: (2021-01-01)